Open AccessEfficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
Author(s) -
Ziyi Xu,
Xuezhi Hao,
Qi Wang,
Jing Wang,
Ke Yang,
Shouzheng Wang,
Fei Teng,
Junling Li,
Puyuan Xing
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s346173
Subject(s) - osimertinib , t790m , medicine , lung cancer , epidermal growth factor receptor , oncology , adenocarcinoma , tyrosine kinase inhibitor , progression free survival , cancer , chemotherapy , gefitinib , erlotinib
Osimertinib is the standard targeted strategy for lung adenocarcinoma patients harboring epidermal growth factor receptor ( EGFR )-activating mutation who have achieved acquired mutation T790M beyond progression of first-line EGFR -tyrosine kinase inhibitor (TKI). In a real world setting, the efficacy for osimertinib as a subsequent treatment beyond first-generation EGFR -TKI progression under complex circumstances such as different T790M mutation status is still worth exploring.